Study of the clinical utility and safety in combination use of the GLP-1 analogue and BG in type 2 diabetic patients

Study of the clinical utility and safety in combination use of the GLP-1 analogue and BG in type 2 diabetic patients - Study of the clinical utility and safety in combination use of the GLP-1 analogue and BG in type 2 diabetic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009636

Enrollment

Registered

2012-12-26

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

liraglutide 0.9mg/day and add on BG 500mg~1500mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HbA1c (NGSP):more than 6.9% Type 2 diabetes Pts with written IC

Exclusion criteria

Exclusion criteria: 1)severe ketosis, diabetic coma within 6 months 2)severe infection, before operation, severe trauma 3)severe hepatic dysfunction 4)or severe renal dysfunction (eGFR: more than 1.5mg/dl) 5)Patients who use of insulin 6)pregnacy 7)Allergy for sitagliptin, nateglinide,liraglutide and exenatide 8)Patients judged by the investigator to be ineligible for some other reason

Design outcomes

Primary

Measure	Time frame
change of HbA1c	—

Countries

Japan

Contacts

Public ContactWakana Miura

Department of Internal Medicine, Tokai University School of Medicine Division of Nephrology, Endocrinology and Metabolism

happy0897@gmail.com0563-93-1121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026